Vascular smooth muscle – indirect cellular targets

Vascular smooth muscle – indirect cellular targets refers to a broad pharmacological classification of proteins and pathways that influence vascular tone without being located directly on the vascular smooth muscle cell (VSMC) membrane. This category primarily includes enzymes and receptors involved in the production or degradation of systemic and paracrine vasoactive agents, such as the renin-angiotensin-aldosterone system (RAAS) and the kallikrein-kinin system [1][2]. For instance, Angiotensin-Converting Enzyme (ACE) is a classic indirect target; its inhibition prevents the formation of Angiotensin II, thereby reducing the stimulus for VSMC contraction and lowering blood pressure [3]. These targets are fundamental in treating cardiovascular diseases, including hypertension, heart failure, and chronic kidney disease, by providing systemic control over peripheral resistance [2]. Because the term describes a functional group of diverse molecular entities rather than a single protein, it is considered a physiological or therapeutic category rather than a specific canonical target [1]. Drugs targeting these pathways often have systemic effects that extend beyond simple vasodilation, including impacts on fluid balance and cardiac remodeling [2].

Other names

Indirect vascular smooth muscle modulatorsNon-direct VSM targetsIndirect modulators of vascular tone

Modulation of the production, degradation, or release of vasoactive ligands (such as Angiotensin II or Bradykinin) that subsequently act on receptors located on vascular smooth muscle cells to induce contraction or relaxation [1][2].